Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kalbe Farma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$3.02T | 16.2x | 3.73 | US$13.50 | -16.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$824.07B | 77.5x | 0.73 | US$920.63 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$434.86B | 30.3x | -0.85 | US$474.96 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$396.41B | 28x | -0.48 | US$165.02 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.4% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$396.06B | 28.3x | 1.29 | US$90.65 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.3% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$366.61B | 86x | -6.94 | US$209.03 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.9% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$278.26B | 30.3x | -1.03 | US$329.35 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$278.26B | 30.3x | -1.03 | US$41.75 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$239.15B | 17.8x | 0.13 | US$138.01 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.6% Downside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$233.99B | 33.3x | 1.8 | US$150.46 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$233.99B | 33.3x | 1.8 | US$76.21 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$231.89B | 13.5x | 0 | US$92.25 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$214.28B | 18.3x | -1.04 | US$110.23 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$214.28B | 18.3x | -1.04 | US$109.05 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.1% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$203.42B | 86.2x | 3.29 | US$573.15 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$199.15B | 31.8x | 4.54 | US$528.96 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$164.92B | 40.3x | -1.01 | US$308.06 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.9% Upside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$153.20B | 81.7x | 4.95 | US$103.79 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$149.21B | 18.4x | 0.07 | US$26.43 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.9% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$148.27B | 38.9x | -2.27 | US$207.76 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.8% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$147.07B | 48.5x | -8.22 | US$386.19 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.9% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$142.26B | 296.8x | -3.12 | US$114.31 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.6% Downside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$136.60B | 54.8x | 57.22 | US$148.24 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -17.3% Downside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$136.25B | 23.7x | 8.08 | US$54.47 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | US$122.80B | -230x | 2.02 | US$479.79 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.1% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$120.48B | -13.4x | 0.06 | US$59.62 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$117.65B | 27.7x | 7.09 | US$92.02 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.7% Upside | Upgrade to Pro+ | |
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | US$89.66B | 15.3x | 8.26 | US$396.88 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.7% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | US$85.28B | 25.2x | -0.8 | US$308.85 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$83.93B | 31.9x | 1.72 | US$25.02 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | US$82.72B | 17.9x | -0.4 | US$65.72 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.2% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$80.12B | 29x | -21.05 | US$640.26 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.4% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$78.29B | 28.5x | 2.59 | US$81.36 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.2% Upside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$75.63B | 13.6x | 0.85 | US$306.30 | -4.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$75.52B | 23.3x | -0.47 | US$18.98 | 4.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$75.52B | 23.3x | -0.47 | US$37.59 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.3% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$74.54B | 17x | 1.65 | US$698.74 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$73.88B | 30.5x | 3.66 | US$167.24 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.2% Upside | Upgrade to Pro+ | |
Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | US$64.37B | 37.5x | 0.92 | US$225.53 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.7% Upside | Upgrade to Pro+ | |
Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$62.54B | 31.8x | 1.02 | US$27.87 | 0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$61.12B | 22x | -3.1 | US$28.21 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.5% Upside | Upgrade to Pro+ | |
Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | US$49.04B | 35.4x | -1.43 | US$253.54 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$45.64B | 67.1x | US$63.15 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | ||
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$45.63B | 32.8x | 2.13 | US$28.10 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alcon | NYSE | Healthcare | Healthcare Equipment & Supplies | US$45.63B | 46.1x | 0.25 | US$92.50 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.2% Upside | Upgrade to Pro+ | |
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$45.63B | 32.8x | 2.09 | US$14.41 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.8% Upside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$43.54B | 25.2x | -10 | US$10.18 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.7% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$43.01B | 26.7x | 0.8 | US$22.95 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | US$42.08B | 10.2x | 0.15 | US$71.62 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12% Upside | Upgrade to Pro+ | |
Hoya Corp | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$41.36B | 29.5x | 1.14 | US$117.49 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.8% Upside | Upgrade to Pro+ |